ABSTRACTAdriamycin® has been shown to be a superoxide‐inducing agent and trimethoprim‐sulfamethoxazole (TMP‐SMZ) has been reported to induce hemolysis in some G6PD deficient patients. Many cancer patients are routinely placed on TMP‐SMZ as prophylaxis againstPneumocystis carniiinfection. Two black A‐ variant G6PD deficient adolescents were treated with combination chemotherapy which included 35 or 50 mg/m2of Adriamycin®. Both were on TMP‐SMZ prophylaxis. No evidence for hemolysis was detectable in either patient by serial determination of hemoglobin, hematocrit, reticulocyte count, and haptoglobin level. Whether this combination will produce hemolysis in other variants of G6PD deficiency needs to be tested.